title: Ultra-low-dose decitabine combined with autologous cytokine-induced killer cells for elderly patients with acute myeloid leukemia transformed from myelodysplastic syndrome.
abstract: OBJECTIVE
  Elderly acute myelocytic leukemia (AML) patients have limited treatment options because they poorly tolerate standard-dose chemotherapy. The present article describes our experience with ultra-low-dose decitabine combined with infusion of autologous cytokine-induced killer (CIK) cells for 2 elderly patients with myelodysplastic syndrome-transformed AML.
  
  
  METHODS
  Decitabine (10 mg) was given on days 1 to 5, and CIK cells on day 14 with 2 to 8 × 10(9) cells per infusion.
  
  
  RESULTS
  The therapeutic regimen resulted in marked hematologic recovery and was associated with better than expected survival in both cases.
  
  
  CONCLUSIONS
  Our experience suggests that the combination therapy is safe and effective for elderly patients with myelodysplastic syndrome-transformed AML.
authors.affiliation: Department of Geriatric Hematology, Chinese PLA General Hospital, Beijing, China; Department of Hematology, First Affiliated Hospital of Chinese PLA General Hospital, Beijing, China.
authors.forename: Haitao
authors.initials: H
authors.lastname: Wang
authors.affiliation: Department of Geriatric Hematology, Chinese PLA General Hospital, Beijing, China.
authors.forename: Bo
authors.initials: B
authors.lastname: Yang
authors.affiliation: Department of Pharmacy, the Second Artillery General Hospital, Beijing, China.
authors.forename: Xiaohua
authors.initials: X
authors.lastname: Chi
authors.affiliation: Department of Geriatric Laboratory Medicine, Chinese PLA General Hospital, Beijing, China.
authors.forename: Lili
authors.initials: L
authors.lastname: Cai
authors.affiliation: Institute of Otorhinolaryngology, Chinese PLA General Hospital, Beijing, China.
authors.forename: Ruili
authors.initials: R
authors.lastname: Yu
authors.affiliation: Department of Geriatric Hematology, Chinese PLA General Hospital, Beijing, China.
authors.forename: Hongli
authors.initials: H
authors.lastname: Zhu
authors.affiliation: Department of Medicine, Chinese PLA No. 202 Hospital, Shenyang, Liaoning, China.
authors.forename: Shuai
authors.initials: S
authors.lastname: Tuo
authors.affiliation: Institute of Genomics, Chinese Academy of Sciences, Beijing, China.
authors.forename: Feng
authors.initials: F
authors.lastname: Zhang
authors.affiliation: Department of Oncology, Dandong Second Hospital, Shenyang, Liaoning, China.
authors.forename: Xuanchi
authors.initials: X
authors.lastname: Wang
authors.affiliation: Department of Geriatric Hematology, Chinese PLA General Hospital, Beijing, China.
authors.forename: Yang
authors.initials: Y
authors.lastname: Yang
authors.affiliation: Department of Hematology, First Affiliated Hospital of Chinese PLA General Hospital, Beijing, China.
authors.forename: Xiaoxiong
authors.initials: X
authors.lastname: Wu
authors.affiliation: Department of Hematology, First Affiliated Hospital of Chinese PLA General Hospital, Beijing, China.
authors.forename: Songwei
authors.initials: S
authors.lastname: Li
authors.affiliation: Department of Geriatric Hematology, Chinese PLA General Hospital, Beijing, China. Electronic address: luxuechun@126.com.
authors.forename: Xuechun
authors.initials: X
authors.lastname: Lu
mesh_terms: D000369:Aged, 80 and over; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage* / Q000627:therapeutic use; D001374:Azacitidine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000097:blood; D003131:Combined Modality Therapy / Q000009:adverse effects; D055612:Cytokine-Induced Killer Cells / Q000637:transplantation*; D000077209:Decitabine; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000473:pathology / Q000628:therapy*; D008297:Male; D009190:Myelodysplastic Syndromes / Q000473:pathology / Q000628:therapy*; D014182:Transplantation, Autologous; D016896:Treatment Outcome
chemical_list: D000964:Antimetabolites, Antineoplastic; D014408:Biomarkers, Tumor; D000077209:Decitabine; D001374:Azacitidine
keywords: AML; CIK cells; MDS; acute myelocytic leukemia; cytokine-induced killer cells; decitabine; elderly; myelodysplastic syndrome